Gubra appoints new CSO
Hørsholm November 1, 2016
Today, Gubra announced a change in its executive management team by appointing Keld Fosgerau as new CSO. With this change, Gubra is able to strengthen its CRO services and further advance the pipeline of internal research and drug discovery projects. Current CSO and co-founder Jacob Jelsing will continue full time in the company, and going forward be focusing on collaborations, as well as maintaining Gubra’s high level of science and innovation.
Gubra CEO Henrik Blou says: “Gubra has experienced significant growth in revenue and customer base over a number of years, and we have grown to more than 75 employees. Following our move to new facilities – we now feel that it is the right time to focus on maturing our internal research programs for partnering. Keld Fosgerau has a profound scientific understanding of diabetes and obesity target and drug discovery and also adds further peptide knowledge to our team”. He continues: “By welcoming Keld to Gubra, we have successfully completed the reshaping of the management team – a process we initiated only earlier this year”.
”The quality of the science and research at Gubra is just tremendous, and in general Gubra is a very progressive organization”, Keld Fosgerau says. “I am honored to join Gubra as CSO and excited to work with our shared passion of understanding metabolic diseases and driving research towards improved therapies”.
About Gubra ApS
Founded in 2008, Gubra is a privately-held biotech company in Hørsholm, Denmark. Gubra focuses on metabolism – notably obesity, diabetes and NASH. Within these core areas, Gubra delivers preclinical services to their partners. In addition to the CRO services, Gubra has several early target and biomarker discovery programs. For more information, please visit the company’s website at www.gubra.dk
About Keld Fosgerau
Keld Fosgerau has more than 16 years of experience from virtual start-ups, established biotechs, CROs, and large integrated pharmaceutical organizations and is highly experience in all aspects from novel target discovery to early clinical development. Previous positions include Vice President (Incretin, Biology and Diabetes Pharmacology) at Novo Nordisk and 6 years of experience from Zealand Pharma (most recently Acting SVP, Head of Research). Keld is highly motivated and passionate about developing organizations, people, and new ideas to create value, with a track record of successful leadership, management, and delivery.
Henrik Blou, Gubra, CEO, firstname.lastname@example.org, +45 2861 6845